A Phase 1 interventional study of Pitavastatin, Valsartan and Livalo® fixed combination drug in Hyperlipidemia and Hypertension, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-03.
Sponsored by JW Pharmaceutical · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Hyperlipidemias with a site in Korea, Republic of — 3 open to participants now, 5 under way, 2 of them phase 3. Hyperlipidemias · Korea, Republic of.
Among the 89 studies in Hyperlipidemias with a site in Korea, Republic of, this one is the 61st largest by enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2011, is one of 39 in phase 1, and was the 10th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →3 of the 89 studies in Hyperlipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of, Argentina, Australia and 11 more countries
Ages 18+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19–55 · Healthy volunteers
Addpharma Inc. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 20 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 4 · Phase 3 31 · Phase 4 8
First in 2004; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 80 across the 85 interventional studies, 3,445 across the 4 observational. Of the 74 that completed or were terminated, 11 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 89 have an industry lead sponsor. The 10 most frequent:
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
JW Pharmaceutical has 4 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
2 of the studies in Hyperlipidemias with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in Hyperlipidemias with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Drug: Pitavastatin, Valsartan
Drug: Pitavastatin, Valsartan
Intervention: Drug: Livalo® fixed combination drug
Drug: Livalo® fixed combination drug
Drug pages: Pitavastatin · Valsartan
Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
Also known as: Livalo, Diovan
Drug pages: Pitavastatin · Valsartan
Livalo® fixed combination drug(1 tablet)
Also known as: Livalo, Diovan
Cmax of study drugs after single oral administration
Time frame: 0-48hrs
AUClast of study drugs after single oral administration
Time frame: 0-48hrs
AUCinf, Tmax and t1/2β of study drugs after single oral administration
Time frame: 0-48hrs
The record gives a start of Aug 2011, a primary completion of Aug 2011 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pitavastatin · Valsartan